Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$7.82 USD

7.82
2,782,954

-0.26 (-3.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.81 -0.01 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IRWD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Ironwood Pharmaceuticals, Inc. [IRWD]

Reports for Purchase

Showing records 981 - 1000 ( 1015 total )

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 981

01/15/2013

Company Report

Pages: 7

Q4:12 EPS, All Eyes on Linzess Launch, We Believe Risks Outweigh Rewards, Reiterate UNDERPERFORM; PT to $11

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 982

01/14/2013

Daily Note

Pages: 7

Weekly Retail Sales Tracker

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 983

01/07/2013

Daily Note

Pages: 7

LINZESS Weekly Retail Sales Tracker

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 984

01/06/2013

Company Report

Pages: 6

$175M Debt Deal Solves Near-Term Cash Crunch at a Cost, We Still Project Significant Cash Needs, Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 985

01/02/2013

Daily Note

Pages: 5

Top-line Plecanatide Data Shows Lower Clinical Benefit Rate vs. Linaclotide and Misses Some Secondary Endpoints - Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 986

10/23/2012

Company Report

Pages: 5

AZ China Deal Nets $25 Million - NEXIUM Co-promote Doesn''t Off-Set LINZESS Detail Costs - Cash Needs Remain - REITERATE UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 987

10/16/2012

Company Report

Pages: 6

Q3:12 Financial Update -- 3 Quarters of Cash - Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 988

10/12/2012

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of October 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 989

09/03/2012

Daily Note

Pages: 5

Pricing Announcement Next, Launch Risks Ahead -- Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 990

08/24/2012

Industry Report

Pages: 16

BIOTECHNOLOGY BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 50.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 991

08/10/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 992

07/17/2012

Company Report

Pages: 6

Q2:12 Financial Update - Awaiting September PDUFA - Reiterate UNDERPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 993

07/13/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 994

07/06/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of July 8

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 995

06/29/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 996

05/25/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 27

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 997

05/18/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 998

05/04/2012

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 999

05/01/2012

Company Report

Pages: 5

Q1:12 Cash Burn Higher Than Expected, We Continue to View Large Financing as Inevitable

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1000

04/27/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party